Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
02 Mayo 2024 - 6:00AM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, announced today that the
Company will be presenting new preclinical data highlighting the
potential of the Company’s HSV-1 based vector platform for back of
the eye gene delivery at the Association for Research in Vision and
Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9,
2024 in Seattle, Washington.
Poster presentation details are as follows:
Title: An HSV-1-Based
Vector Platform for Localized Delivery to the Posterior of the
EyePresenter: Haley Nicole
CartwrightDate and Time: May 7,
2024 from 3:30PM to 5:15PM PTPosterboard
Number: B0022Abstract Number: 3978 -
B0022
The poster will be available to conference attendees. Following
the presentation, the poster will also be available to view online
on the Investor section of the Company’s website.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK® is the Company’s first commercial product, the first-ever
redosable gene therapy, and the first medicine approved by the FDA
for the treatment of dystrophic epidermolysis bullosa. The Company
is rapidly advancing a robust preclinical and clinical pipeline of
investigational genetic medicines in respiratory, oncology,
dermatology, ophthalmology, and aesthetics. Krystal Biotech is
headquartered in Pittsburgh, Pennsylvania. For more information,
please visit http://www.krystalbio.com, and follow @KrystalBiotech
on LinkedIn and X (formerly Twitter).
CONTACTInvestors and Media:
Stéphane Paquette, PhDKrystal
Biotechspaquette@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Krystal Biotech (NASDAQ:KRYS)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024